Lymphoma

Bortezomib falls in the category of proteasome inhibitors. It is indicated for multiple myeloma and mantle-cell lymphoma. The medicine inhibits the production of proteins that are important for the growth and multiplication of cancer cells. In addition, the medicine also blocks the action of proteasome and slows down the rate of growth of cancerous actively growing cells. It is recommended as a targeted therapy and also given after other cancer medications have been unsuccessful.

Bortenat 2mg Injection is intended for multiple myeloma and mantle-cell lymphoma. The medicine works by inhibiting the production of proteins which have an important role in the growth and multiplication of cancer cells. The medicine belongs to the class of drugs called proteasome inhibitors. It works by blocking the action of proteasome, thus reducing the growth of cancerous (actively growing) cells.